ModernaCHIX:0QFD 67 Receivables Turnover is 3.08 as of Mar. 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 67/100 and a GF Value™ of €14.54 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, Moderna ranks better than 68.13% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Moderna's Revenue for the
three
months ended in Mar. 2026 was €336 Mil. Moderna's average Accounts Receivable for the
three
months ended in Mar. 2026 was €109 Mil.
Hence, Moderna's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.08.
Moderna (CHIX:0QFd) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Moderna Receivables Turnover Related Terms
Moderna Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Moderna's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:0QFD vs RPRX, ROIV, ONC: Receivables Turnover Comparison
For the Biotechnology subindustry, Moderna's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Moderna's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (CHIX:0QFD) has a Receivables Turnover of 3.08 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Moderna and its competitors. According to the industry distribution chart, Moderna ranks #268 out of 841 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Moderna's Receivables Turnover too high?
Moderna's current Receivables Turnover is 3.08. The Biotechnology industry median Receivables Turnover is 5.29. Moderna's value of 3.08 is 41.8% below this industry median. Based on the distribution chart, Moderna ranks #268 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moderna has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's Receivables Turnover compare to RPRX and ROIV?
According to the Biotechnology industry distribution chart, Moderna ranks #268 out of 841 companies for Receivables Turnover. This puts Moderna in the upper half of its industry. The industry median Receivables Turnover is 5.29. Moderna's value of 3.08 is 41.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moderna's current Receivables Turnover of 3.08 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Moderna and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moderna's current Receivables Turnover is 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €14.54, compared to a current price of €70.49 — trading 384.8% above its estimated fair value. The current Receivables Turnover is 3.08 and 41.8% below the Biotechnology industry median of 5.29. Moderna's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current Receivables Turnover is 3.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (CHIX:0QFD) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of €70.49 is trading 384.8% above its estimated GF Value™ of €14.54.
GuruFocus considers Moderna to be Significantly Overvalued.
Key valuation signals for CHIX:0QFD:
Receivables Turnover: 3.08
GF Value™: €14.54 vs. price of €70.49 (384.8% above fair value)
Industry Position: 41.8% below the Biotechnology median (#268 of 841)
No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
67GF Score
Get the complete analysis for CHIX:0QFD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:0QFD has been successfully added to your 
